tirzepatide clinical trial results cardiovascular outcomes july 2025 Reduction of prevalence of patients meeting the criteria for Who Is Tirzepatide Right For?

If Im going to ask Claude to help me organize my week (and I am, I would be lost without him at this point), the least I can do is recycle my needles

Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q, et al

If nausea lingers or worsens, talk to your doctor about possible adjustments to your plan, such as reducing your dose or exploring other potential treatments

Back to Journals Clinical Ophthalmology Volume 20 Glucagon-Like Peptide-1 Analogs Associated with a Reduced Risk of Legal Blindness in Type 2 Diabetics with Cardiovascular Risks Authors Jarrett E, Muayad J , Ryu BU, Lee AG, Gupta PK Received 1 December 2025 Accepted for publication 28 January 2026 Published 3 February 2026 Volume 2026:20 581826 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Yousef Fouad Ethan Jarrett, 1 Jawad Muayad, 2 Byoung U Ryu, 3 Andrew G Lee, 1 8 Praveena K Gupta 3 1 John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX, USA